Back to top

Craig-Hallum bullish on Alterity Therapeutics, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Alterity Therapeutics (ATHE) with a Buy rating and $12 price target The firm sees Alteri...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Alterity Therapeutics Limited - Sponsored ADR (ATHE)